Search Results

You are looking at 1 - 10 of 953 items :

  • "thyroglobulin" x
Clear All

Clin Chem Lab Med 2011;49(6):1025–1027 2011 by Walter de Gruyter • Berlin • Boston. DOI 10.1515/CCLM.2011.155 2010/693 Article in press - uncorrected proof Short Communication Comparison of thyroglobulin antibody interference in first- and second-generation thyroglobulin immunoassays Luca Giovanella1,2,* and Luca Ceriani1 1 Nuclear Medicine and Thyroid Centre, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland 2 Clinical Chemistry, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland Abstract Background: This study evaluated the

Clin Chem Lab Med 2007;45(8):1058–1064 2007 by Walter de Gruyter • Berlin • New York. DOI 10.1515/CCLM.2007.185 2007/9 Article in press - uncorrected proof Biological variation of thyroid autoantibodies and thyroglobulin Esther Jensen1,*, Per Hyltoft Petersen2, Ole Blaabjerg1 and Laszlo Hegedüs3 1 Department of Clinical Biochemistry, Odense University Hospital, Odense, Denmark 2 NOKLUS, Norwegian quality improvement of primary care laboratories, Division for General Practice, University of Bergen, Bergen, Norway 3 Department of Endocrinology and Metabolism

References 1. Cooper DS, Doherty GM, Haugen BR, et al. (2009). Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 19:1167-1214. 2. Pacini F, Schlumberger M, Dralle H, et al. (2006). European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol, 154:787-803. 3. Feldt-Rasmussen U, Profilis C, Colinet E, et al. (1996). Human thyroglobulin reference material (CRM 457). 1st part: assessment of homogeneity

Clin Chem Lab Med 2008;46(8):1067–1073 2008 by Walter de Gruyter • Berlin • New York. DOI 10.1515/CCLM.2008.212 2007/561 Article in press - uncorrected proof Minireview Highly sensitive thyroglobulin measurements in differentiated thyroid carcinoma management Luca Giovanella* Department of Nuclear Medicine, PET Center and Thyroid Unit, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland Abstract Differentiated thyroid cancer is an infrequent disease with a generally good prognosis. The initial treatment is total thyroidectomy coupled with

Introduction Thyroglobulin (Tg) is a large, 660-kDa, glycoprotein which normally is stored in the follicular colloid of the thyroid gland where it acts as a substrate for thyroid hormone production. As it is only produced by benign or well-differentiated malignant thyroid cells, it is a very good tumor marker for patients with differentiated thyroid carcinoma (DTC) [1], especially after removal of all benign and malignant thyroid tissue through surgery and I-131 ablation [2]. Over the years, the sensitivity and precision of Tg assays have improved by multiple

Introduction Serum thyroglobulin (Tg) is the primary tumor marker used to monitor differentiated thyroid cancer (DTC) after initial treatment [ 1 ], [ 2 ], [ 3 ]. In addition, Tg testing before post-surgical radioiodine ablation (RRA) of thyroid remnant is proved to be a readily available and inexpensive tool with a high negative predictive value for future disease-free status [ 4 ]. However, thyroglobulin autoantibodies (TgAb) may be detected in 15%–40% of DTC patients; i.e. roughly twice or more as often as in the general population [ 5 ], and Tg measurement is

Introduction Thyroid diseases are very common, and thyroid carcinomas represent the most frequent endocrine malignancies [ 1 ], [ 2 ]. Differentiated thyroid carcinomas (DTC), such as papillary (PTC) and follicular (FTC) histologic types, develop from thyrocytes and produce exclusively thyroglobulin (Tg). Then, these patients are followed up over time by monitoring their serum Tg levels and using local and whole-body imaging techniques (i.e. neck ultrasound, whole-body scintiscan, and 18-FDG-PET/TC) [ 3 ]. A rate up to 50% of DTC patients have metastatic neck

-42. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006; 154: 787-803. Ito Y, Uruno T, Nakano K, Fukushima M, Kihara M, Higashiyama T, et al. An observation trial without surgical treatment in patients with papillary microcarcinoma of thyroid. Thyroid 2003; 13: 381-7. Van Herle AJ, Vassart G, Dumont JE. Control of thyroglobulin synthesis and secretion. (First of two parts). N Engl J Med 1979; 301: 239-49. Sinadinović J

Introduction Measurement of thyroglobulin (Tg) has become a pivotal part of the monitoring of patients with differentiated thyroid cancer (DTC). Numerous studies have shown that both unstimulated and stimulated Tg results that are very low or undetectable with modern noncompetitive immunometric assays (i.e. with functional sensitivity [FS] of 0.1–0.2 μg/L) indicate individuals with a very low likelihood of progression [ 1 ], [ 2 ], [ 3 ], [ 4 ]. Unfortunately, anti-thyroglobulin autoantibodies (TgAb) are present in 15%–30% of patients with DTC and hamper the use

Introduction Serum thyroglobulin (Tg) measurement, an important part of thyroid cancer follow-up, is affected in the 15-30% of patients who have anti-Tg autoantibodies (TgAb), which frequently lead to false low Tg measurements in immunometric Tg assays (Tg-IA) [ 1 ]. To overcome these limitations, Tg mass spectrometry assays (Tg-MS) have been developed. Tg-MS detects Tg proteotypic peptides after digestion of serum proteins with trypsin [ 2 ], [ 3 ], [ 4 ]. This eliminates TgAb interferences. However, the limit of quantitation (LOQ) of current Tg-MS assays is